Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient

Azalea Therapeutics, a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to advance its proprietary Enveloped Delivery Vehicle (EDV) technology. The company’s mission is to engineer therapeutic cells with precision directly inside the patient, transforming how cell and gene therapies are created and delivered.

Justin Eyquem is the lead UCSF inventor. We congratulate his success.

More